JP2014510149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510149A5 JP2014510149A5 JP2014503996A JP2014503996A JP2014510149A5 JP 2014510149 A5 JP2014510149 A5 JP 2014510149A5 JP 2014503996 A JP2014503996 A JP 2014503996A JP 2014503996 A JP2014503996 A JP 2014503996A JP 2014510149 A5 JP2014510149 A5 JP 2014510149A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- dimethylamine
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 16
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 14
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 7
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- -1 Y is S Chemical compound 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 6
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472061P | 2011-04-05 | 2011-04-05 | |
| US61/472,061 | 2011-04-05 | ||
| PCT/US2012/032373 WO2012138896A1 (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510149A JP2014510149A (ja) | 2014-04-24 |
| JP2014510149A5 true JP2014510149A5 (enExample) | 2015-05-21 |
| JP5961683B2 JP5961683B2 (ja) | 2016-08-02 |
Family
ID=46018086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014503996A Expired - Fee Related JP5961683B2 (ja) | 2011-04-05 | 2012-04-05 | Ｈｓｐ９０阻害物質 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9546170B2 (enExample) |
| EP (1) | EP2694506B1 (enExample) |
| JP (1) | JP5961683B2 (enExample) |
| KR (1) | KR101984480B1 (enExample) |
| CN (1) | CN103596955B (enExample) |
| AU (1) | AU2012240079B2 (enExample) |
| BR (1) | BR112013025761A2 (enExample) |
| CA (1) | CA2832099C (enExample) |
| EA (1) | EA024647B1 (enExample) |
| ES (1) | ES2647889T3 (enExample) |
| MX (1) | MX354215B (enExample) |
| WO (1) | WO2012138896A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| PT2486039T (pt) | 2009-10-07 | 2016-09-06 | Sloan Kettering Inst For Cancer Res | Derivados de purina úteis como inibidores de hsp90 |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| AU2012240077C1 (en) | 2011-04-05 | 2017-08-10 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| ES2624982T3 (es) | 2011-07-08 | 2017-07-18 | Sloan-Kettering Institute For Cancer Research | Usos de inhibidores etiquetados HSP90 |
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| KR102319582B1 (ko) | 2013-08-16 | 2021-11-04 | 메모리얼 슬로안 케터링 캔서 센터 | 선택적 ｇｒｐ９４ 저해제 및 이의 용도 |
| MX2016008418A (es) | 2013-12-23 | 2017-01-11 | Memorial Sloan Kettering Cancer Center | Metodos y reactivos para el radiomarcaje. |
| CA3289739A1 (en) | 2014-06-24 | 2025-11-29 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| EP3194975A4 (en) | 2014-09-17 | 2018-05-02 | Memorial Sloan Kettering Cancer Center | Hsp90-targeted inflammation and infection imaging and therapy |
| JP7132848B2 (ja) | 2015-10-05 | 2022-09-07 | メモリアル スローン ケタリング キャンサー センター | 癌の治療のための合理的併用療法 |
| MX2025007723A (es) | 2018-05-14 | 2025-08-01 | Reata Pharmaceuticals Inc | Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor |
| WO2023006993A1 (en) | 2021-07-30 | 2023-02-02 | Atmosr | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome |
| JP2026509913A (ja) * | 2023-03-17 | 2026-03-25 | アトモスアール | Ｈｓｐ９０阻害剤としてのアデニン誘導体 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE460423T1 (de) | 1997-05-14 | 2010-03-15 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
| AU769235B2 (en) | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| WO2003041643A2 (en) | 2001-11-09 | 2003-05-22 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| NZ535592A (en) | 2002-02-28 | 2006-07-28 | Astrazeneca Ab | 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents |
| US7592143B2 (en) | 2003-04-18 | 2009-09-22 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| NZ546611A (en) | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| ZA200801822B (en) | 2005-08-26 | 2009-09-30 | Serono Lab | Pyrazine derivatives and use as p13k inhibitors |
| WO2007075572A2 (en) | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
| AU2007249194B2 (en) | 2006-05-12 | 2012-11-22 | Myrexis, Inc. | Therapeutic compounds and their use in cancer |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| SG174772A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| FR2906824B1 (fr) | 2006-10-09 | 2008-12-26 | Roger Mondelin Sas Soc Par Act | Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| EA019103B1 (ru) | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| WO2008115262A2 (en) | 2007-03-20 | 2008-09-25 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
| EP2183221A1 (en) | 2007-07-12 | 2010-05-12 | Crystax Pharmaceuticals S.L. | New compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| AU2008322503A1 (en) | 2007-11-14 | 2009-05-22 | Myrexis, Inc. | Therapeutic compounds and their use in treating diseases and disorders |
| CA3017874A1 (en) | 2009-01-16 | 2010-07-22 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
| PT2486039T (pt) | 2009-10-07 | 2016-09-06 | Sloan Kettering Inst For Cancer Res | Derivados de purina úteis como inibidores de hsp90 |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| AU2012240077C1 (en) | 2011-04-05 | 2017-08-10 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| KR102319582B1 (ko) | 2013-08-16 | 2021-11-04 | 메모리얼 슬로안 케터링 캔서 센터 | 선택적 ｇｒｐ９４ 저해제 및 이의 용도 |
-
2012
- 2012-04-05 MX MX2013011531A patent/MX354215B/es active IP Right Grant
- 2012-04-05 ES ES12717521.4T patent/ES2647889T3/es active Active
- 2012-04-05 JP JP2014503996A patent/JP5961683B2/ja not_active Expired - Fee Related
- 2012-04-05 US US14/110,095 patent/US9546170B2/en active Active
- 2012-04-05 CN CN201280027360.XA patent/CN103596955B/zh not_active Expired - Fee Related
- 2012-04-05 KR KR1020137029258A patent/KR101984480B1/ko not_active Expired - Fee Related
- 2012-04-05 AU AU2012240079A patent/AU2012240079B2/en not_active Ceased
- 2012-04-05 WO PCT/US2012/032373 patent/WO2012138896A1/en not_active Ceased
- 2012-04-05 BR BR112013025761A patent/BR112013025761A2/pt not_active IP Right Cessation
- 2012-04-05 EA EA201391337A patent/EA024647B1/ru not_active IP Right Cessation
- 2012-04-05 EP EP12717521.4A patent/EP2694506B1/en active Active
- 2012-04-05 CA CA2832099A patent/CA2832099C/en active Active
-
2016
- 2016-12-09 US US15/374,007 patent/US10064867B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515561A5 (enExample) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2012508252A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| CN113784970A (zh) | Erk抑制剂及其应用 | |
| MX2013011531A (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
| JP2016532667A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| MX2018010878A (es) | Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| JP2011529918A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2016519653A5 (enExample) | ||
| JP2016527217A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| JP2016503797A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2016507575A5 (enExample) | ||
| JP2016531871A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| JP2014523413A5 (enExample) |